@article{8697694,
  abstract     = {{Objectives Janus kinase inhibitors (JAKi) have been approved for use in various immune-mediated inflammatory diseases. With five agents licensed, it was timely to summarise the current understanding of JAKi use based on a systematic literature review (SLR) on efficacy and safety. Methods Existing data were evaluated by a steering committee and subsequently reviewed by a 29 person expert committee leading to the formulation of a consensus statement that may assist the clinicians, patients and other stakeholders once the decision is made to commence a JAKi. The committee included patients, rheumatologists, a gastroenterologist, a haematologist, a dermatologist, an infectious disease specialist and a health professional. The SLR informed the Task Force on controlled and open clinical trials, registry data, phase 4 trials and meta-analyses. In addition, approval of new compounds by, and warnings from regulators that were issued after the end of the SLR search date were taken into consideration. Results The Task Force agreed on and developed four general principles and a total of 26 points for consideration which were grouped into six areas addressing indications, treatment dose and comedication, contraindications, pretreatment screening and risks, laboratory and clinical follow-up examinations, and adverse events. Levels of evidence and strengths of recommendations were determined based on the SLR and levels of agreement were voted on for every point, reaching a range between 8.8 and 9.9 on a 10-point scale. Conclusion The consensus provides an assessment of evidence for efficacy and safety of an important therapeutic class with guidance on issues of practical management.}},
  author       = {{Nash, Peter and Kerschbaumer, Andreas and Doerner, Thomas and Dougados, Maxime and Fleischmann, Roy M. and Geissler, Klaus and McInnes, Iain and Pope, Janet E. and van der Heijde, Desiree and Stoffer-Marx, Michaela and Takeuchi, Tsutomu and Trauner, Michael and Winthrop, Kevin L. and de Wit, Maarten and Aletaha, Daniel and Baraliakos, Xenofon and Boehncke, Wolf-Henning and Emery, Paul and Isaacs, John D. and Kremer, Joel and Lee, Eun Bong and Maksymowych, Walter P. and Voshaar, Marieke and Tam, Lai-Shan and Tanaka, Yoshiya and Van den Bosch, Filip and Westhovens, Rene and Xavier, Ricardo and Smolen, Josef S.}},
  issn         = {{0003-4967}},
  journal      = {{ANNALS OF THE RHEUMATIC DISEASES}},
  keywords     = {{MODIFYING ANTIRHEUMATIC DRUGS,ACTIVE PSORIATIC-ARTHRITIS,INTERLEUKIN-6,RECEPTOR INHIBITION,RHEUMATOID-ARTHRITIS,DOUBLE-BLIND,INADEQUATE,RESPONSE,VENOUS THROMBOEMBOLISM,EULAR RECOMMENDATIONS,MAINTENANCE,THERAPY,HERPES-ZOSTER}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{71--87}},
  title        = {{Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors : a consensus statement}},
  url          = {{http://doi.org/10.1136/annrheumdis-2020-218398}},
  volume       = {{80}},
  year         = {{2021}},
}

Altmetric

View in Altmetric

Web of Science

Times cited: